Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Sr. VP of IP, CSO | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,795 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Exercise / conversion · Acquired 2,500 · Balance 19,795 F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 18,637 |
Reported balance
After 2026-08-12 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-12 · Tax withholding · Disposed 1,158 · Balance 18,637 F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-12 · Exercise / conversion · Disposed 2,500 · Balance 0 F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 05, 2025 Filed Mar 5, 2025 21:21 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 335 | $33.05 | $11,071.75 |
DisclosureSEC source: 0001628280-25-010483 · wk-form4_1741209670.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,854 F1 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Restricted Stock Units. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 01:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007534 · wk-form4_1740446545.xml · derivative · entry 9 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,500 Underlying: Common Stock · 1,250 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F7 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. F7 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2025 Filed Feb 25, 2025 01:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007534 · wk-form4_1740446545.xml · nonDerivative · entry 5 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,189 Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007534 · wk-form4_1740446545.xml · derivative · entry 8 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,750 Underlying: Common Stock · 1,250 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F6 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. F6 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007534 · wk-form4_1740446545.xml · derivative · entry 7 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 750 Underlying: Common Stock · 750 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F5 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. F5 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007534 · wk-form4_1740446545.xml · nonDerivative · entry 4 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,939 Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 01:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007534 · wk-form4_1740446545.xml · nonDerivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,689 Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 01:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Units · Derivative | 1,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007534 · wk-form4_1740446545.xml · derivative · entry 6 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,650 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F3 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 01:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 860 | $39.15 | $33,669.00 |
DisclosureSEC source: 0001628280-25-007534 · wk-form4_1740446545.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,939 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| February 21, 2025 Filed Feb 25, 2025 01:22 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007534 · wk-form4_1740446545.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,799 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 22, 2024. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:45 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007170 · wk-form4_1740174332.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,500 Underlying: Common Stock · 4,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 21:45 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $33.52 | $0.00 |
DisclosureSEC source: 0001628280-25-007170 · wk-form4_1740174332.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2035-02-19 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 19, 2026. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:37 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 9,477 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001628280-25-004073 · wk-form4_1738791425.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,250 Underlying: Common Stock · 9,477 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested in four equal installments beginning on February 19, 2022. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:37 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 9,477 | $39.70 | $376,236.90 |
DisclosureSEC source: 0001628280-25-004073 · wk-form4_1738791425.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,149 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $39.90. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:37 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 9,477 | $29.61 | $280,613.97 |
DisclosureSEC source: 0001628280-25-004073 · wk-form4_1738791425.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,626 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · derivative · entry 7 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,477 Underlying: Common Stock · 700 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal installments beginning on February 19, 2022. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Units · Derivative | 1,650 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · derivative · entry 6 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,650 Underlying: Common Stock · 1,650 shares Expires not disclosed F5 · derivative.exercise_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. F5 · derivative.expiration_date: On February 22, 2024, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 24, 2024. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 700 | $39.62 | $27,734.00 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · nonDerivative · entry 4 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,149 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $39.63. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 28, 2025 Filed Jan 29, 2025 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 700 | $29.61 | $20,727.00 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · nonDerivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,849 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 28, 2025 Filed Feb 5, 2025 21:33 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 700 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001628280-25-004067 · wk-form4a_1738791207.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,727 Underlying: Common Stock · 700 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested in four equal installments beginning on February 19, 2022. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 2,573 | $0.00 Strike: $29.61 | $0.00 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · derivative · entry 5 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,177 Underlying: Common Stock · 2,573 shares Expires 2031-02-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal installments beginning on February 19, 2022. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 2,573 | $39.62 | $101,942.26 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,149 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.61 to $39.67. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| January 27, 2025 Filed Jan 29, 2025 22:04 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 2,573 | $29.61 | $76,186.53 |
DisclosureSEC source: 0001628280-25-003018 · wk-form4_1738188277.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,722 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes an aggregate of 470 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,745 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · derivative · entry 6 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,745 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 24, 2018. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 8,750 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · derivative · entry 5 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,750 shares Expires 2030-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 21, 2021. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 12,745 | $36.68 | $467,486.60 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · nonDerivative · entry 4 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,679 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.24 to $37.00. The Reporting Person undertakes to provide to Supernus, any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 12,745 | $25.30 | $322,448.50 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · nonDerivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,424 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 8,750 | $36.68 | $320,950.00 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,679 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.29 to $37.01. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| December 03, 2024 Filed Dec 4, 2024 21:36 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 8,750 | $23.99 | $209,912.50 |
DisclosureSEC source: 0001628280-24-049934 · wk-form4_1733348181.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 20, 2024 Filed Aug 20, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 1,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-091319 · tm2422059-1_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| August 20, 2024 Filed Aug 20, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 572 | $29.57 | $16,914.04 |
DisclosureSEC source: 0001104659-24-091319 · tm2422059-1_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,679 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. Read SEC document |
| August 20, 2024 Filed Aug 20, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-091319 · tm2422059-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain Performance Share Units granted to the Reporting Person on February 23, 2023. Read SEC document |
| August 01, 2024 Filed Aug 14, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 1,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-089719 · tm2421712-1_4seq1.xml · derivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,250 Underlying: Common Stock · 1,250 shares Expires not disclosed F2 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F2 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 14,491 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-24-038482 · tm249377-3_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,745 Underlying: Common Stock · 14,491 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 24, 2018. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 14,491 | $35.31 | $511,677.21 |
DisclosureSEC source: 0001104659-24-038482 · tm249377-3_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,570 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $35.43. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 21, 2024 Filed Mar 25, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 14,491 | $25.30 | $366,622.30 |
DisclosureSEC source: 0001104659-24-038482 · tm249377-3_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 400 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-24-037934 · tm249377-2_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,236 Underlying: Common Stock · 400 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F2 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 24, 2018. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 400 | $35.31 | $14,124.00 |
DisclosureSEC source: 0001104659-24-037934 · tm249377-2_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,570 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. Read SEC document |
| March 20, 2024 Filed Mar 22, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 400 | $25.30 | $10,120.00 |
DisclosureSEC source: 0001104659-24-037934 · tm249377-2_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,970 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 21:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 12,364 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-24-037376 · tm249377-1_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,636 Underlying: Common Stock · 12,364 shares Expires 2027-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 24, 2018. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 21:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 12,364 | $35.31 | $436,572.84 |
DisclosureSEC source: 0001104659-24-037376 · tm249377-1_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,570 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.30 to $35.34. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 21:01 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 12,364 | $25.30 | $312,809.20 |
DisclosureSEC source: 0001104659-24-037376 · tm249377-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,934 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 22:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 26,250 | $0.00 Strike: $23.99 | $0.00 |
DisclosureSEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · derivative · entry 6 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,750 Underlying: Common Stock · 26,250 shares Expires 2030-02-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F5 · derivative.exercise_date: The option vested in four equal annual installments beginning on February 21, 2021. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 22:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 36,116 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · derivative · entry 5 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 36,116 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F4 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 1, 2017. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 22:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 36,116 | $33.48 | $1,209,163.68 |
DisclosureSEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · nonDerivative · entry 4 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,570 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.98 to $33.74. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 22:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 36,116 | $12.98 | $468,785.68 |
DisclosureSEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · nonDerivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 22:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 26,250 | $34.10 | $895,125.00 |
DisclosureSEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,570 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.99 to $34.28. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
| March 13, 2024 Filed Mar 15, 2024 22:39 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 26,250 | $23.99 | $629,737.50 |
DisclosureSEC source: 0001104659-24-035104 · tm248954-1_4seq1.xml · nonDerivative · entry 1 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,820 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 3,884 | $0.00 Strike: $12.98 | $0.00 |
DisclosureSEC source: 0001104659-24-034563 · tm248830-1_4seq1.xml · derivative · entry 3 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,116 Underlying: Common Stock · 3,884 shares Expires 2026-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F3 · derivative.exercise_date: The option vested in four equal annual installments beginning on March 1, 2017. Read SEC document |
| March 12, 2024 Filed Mar 14, 2024 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | SaleCommon Stock | 3,884 | $32.99 | $128,133.16 |
DisclosureSEC source: 0001104659-24-034563 · tm248830-1_4seq1.xml · nonDerivative · entry 2 Bhatt Padmanabh P. · CIK 0001539215 · Sr. VP of IP, CSO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,570 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted September 7, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.98 to $33.00. The Reporting Person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.